Search - tctmd.com

Displaying 581 - 600 of 1793

Sort: Relevancy | Date

Intensive BP Control May Stave Off LV Conduction Disease: SPRINT

News Conference News HRS 2022

Intensive BP Control May Stave Off LV Conduction Disease: SPRINT

May 02, 2022

May 2022 News Roundup

News Opinion CV Team Dispatch

May 2022 News Roundup

May 01, 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

News Daily News

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

Michael O'Riordan

April 27, 2022

USPSTF Finalizes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF Finalizes Tougher Stance on Aspirin in Primary Prevention

April 26, 2022

Update on Pharmacology in the Cath Lab

Presentation ARCH 2022

Update on Pharmacology in the Cath Lab

Presenter: James B. Hermiller

April 23, 2022

Current Status and Future of Renal Denervation for Hypertension

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

Statin Use, at Any Dose, Not Linked to Excess Dementia Risk in FH

News Daily News

Statin Use, at Any Dose, Not Linked to Excess Dementia Risk in FH

Yael L. Maxwell

April 22, 2022

Myocarditis Risk Varies Among mRNA-Based COVID-19 Vaccines

News Daily News

Myocarditis Risk Varies Among mRNA-Based COVID-19 Vaccines

April 21, 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

April 06, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

The PACMAN AMI Randomized Clinical Trial

Presentation ACC 2022

The PACMAN AMI Randomized Clinical Trial

Presenter: Lorenz Räber

April 04, 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

TRANSLATE-TIMI 70

Presentation ACC 2022

TRANSLATE-TIMI 70

Presenter: Brian Bergmark

April 04, 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.